NCT07215910 - Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | Biotech Hunter

Enrollment

408

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

May 31, 2033

Study Completion Date

January 31, 2040

Conditions

Astrocytoma, IDH-Mutant, Grade 3

Interventions

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT/VMAT

RADIATION

Volume Modulated Arc Therapy

Undergo IMRT/VMAT

RADIATION

Pencil Beam Scanning

Undergo PBS

PROCEDURE

Intensity-Modulated Proton Therapy

Undergo IMPT

DRUG

Temozolomide

Given PO

DRUG

Vorasidenib

Given PO

DRUG

Placebo Administration

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Questionnaire Administration

Ancillary Studies

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER